Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2022.4330
Abstract: Little is known about different Ixekizumab (IXE) dosing regimens during routine clinical practice. To evaluate the real-world effectiveness and safety of different IXE dosing regimens in patients with psoriasis. This study retrospectively compared patients who… read more here.
Keywords: four week; dermatology; two week; week dosing ... See more keywords